News

From lids to retina, the 2-day event on September 26 and 27, 2025, at the Margaritaville Hollywood Beach Resort, Florida, offers a collaborative and comprehensive experience with actionable takeaways.

We ask leading experts in the field what eye disease they would cure and why.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.

Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

The start of the series that asks leading experts in the field what eye disease they would cure and why.

A study reveals Hispanic patients face lower success rates in trabeculectomy with MMC compared to European patients, highlighting significant disparities in glaucoma surgery outcomes.

Dr. Tanna will kick off the new monthly subspecialty education series with a virtual session on September 9, 2025, focused on using OCT imaging and perimetry to track glaucoma progression.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

Course director Robert S. Feder, MD, shares how the monthly Zoom sessions aim to deliver clinical pearls and foster cross-subspecialty learning.

Ashvattha Therapeutics reveals phase 2 results for migaldendranib, showing significant vision improvements and reduced injection needs in retinal disease patients.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

OpZira Inc. launches innovative ophthalmic diagnostic tools, enhancing early detection and monitoring of ocular diseases for improved patient outcomes.

VirtuaLens revolutionizes cataract care with its VR IOL Simulator, empowering patients to make informed lens choices through immersive experiences.

This marks the first time that the TearCare System has been included in the TFOS DEWS III Management and Therapy Report.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared to nonpregnant controls.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

Identifeye HEALTh is taking on retinal imaging, enhancing accessibility and integrating AI to improve patient care and streamline healthcare workflows.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.